Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




POC Chlamydia and Gonorrhea Combo Test Gives Results in 30 Minutes

By LabMedica International staff writers
Posted on 16 Aug 2023

Despite the existence of highly sensitive and specific laboratory-based molecular diagnostic tools, the U. More...

S. has seen a steady rise in Chlamydia trachomatis and Neisseria gonorrhea (CT/NG) infections in recent years. Surprisingly, about 50% of eligible women don't get screened for these STIs according to the guidelines laid down by the Centers for Disease Control and Prevention (CDC). The traditional testing processes for CT/NG often lead to less-than-ideal outcomes. Patients sometimes receive potentially inappropriate treatments, may not always comply with prescribed treatments, and might face a treatment delay, having to wait nearly 10 days for lab results. By introducing rapid point-of-care (POC) tests, the time between diagnosing and treating these STIs can be reduced, subsequently lowering the chances of further transmission and related complications.

The binx io Platform from binx health (Boston, MA, USA) is the first FDA-approved, CLIA-Waived CT/NG molecular test suitable for both genders, enabling on-the-spot diagnosis and treatment. This platform can deliver results equivalent to those of lab-based tests in just about 30 minutes, in contrast to the days or weeks often required by traditional methods. The binx io platform combines the binx health io CT/NG Assay, an automated, fast, and qualitative test, and the binx health io Instrument, to detect CT/NG DNA using the polymerase chain reaction (PCR) process. By combining ultra-rapid PCR with unique electrochemical detection, the platform ensures results that are as reliable as those available from central labs. The desktop-sized device is user-friendly, allowing operation by staff who might not have formal lab training, even in CLIA-Waived environments.

The binx health io CT/NG Assay is a versatile test; it can use swabs from females (either clinician-collected or self-collected in a clinic) or male urine samples to diagnose CT/NG infections. A recent study compared the workflow of the io CT/NG Assay to traditional lab-based tests. Findings revealed that the time clinic staff spent operating the binx io CT/NG test wasn't statistically different from the time spent preparing samples for a lab. Essentially, while the tasks might differ, the total time spent remains similar. The major advantage, however, is that the binx io delivers actionable results in roughly 30 minutes. This means it can integrate smoothly into a typical patient visit, shifting the focus from sending out samples for lab testing to immediate in-clinic testing without creating an extra workload for the clinic staff.

“The data further support that the binx io provided test results reasonable for a single patient-visit compared to 16 hours for the laboratory-based results,” said Jeffrey Luber, Chief Executive Officer of binx health. “This time-to-result is extremely important for providing clinically actionable information and improving the quality of a patient’s care.”

Related Links:
binx health 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Homocysteine Quality Control
Liquichek Homocysteine Control
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.